A new analysis shows that individuals with employer insurance could save 41% on their out-of-pocket spending for asthma and COPD inhalers through manufacturer savings. In response to a U.S. Senate investigation into inhaler costs, 3 drug makers voluntarily capped out-of-pocket costs on their brand-name asthma and COPD inhalers. Among the asthma and COPD inhalers covered under the voluntary out-of-pocket spending caps, over half may have patient savings of $19 or less per 30-day supply: https://on.kff.org/4fwxX6F
